Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07424677 Saroglitazar Primary Biliary Cholangitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07424677 clinical trial report covering Saroglitazar, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07427797 Botulinum toxin A(Medytox) Glabellar frown lines Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07427797 clinical trial report covering Botulinum toxin A(Medytox), Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07424287 SHR-1501 Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07424287 clinical trial report covering SHR-1501, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07426081 Dexmedetomidine Hydrochloride Postoperative Nausea and Vomiting Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07426081 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07429708 Ropivacaine Hydrochloride Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07429708 clinical trial report covering Ropivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07428499 Onvuzosiran Hereditary Angioedema Types I and II Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07428499 clinical trial report covering Onvuzosiran, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07429734 Solifenacin Succinate Urinary Bladder, Overactive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07429734 clinical trial report covering Solifenacin Succinate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071250134 Selexipag Intermittent Claudication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
JPRN-jRCT2071250134 clinical trial report covering Selexipag, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07431281 Nivolumab Claudin18.2-positive / HER2-negative Solid Tumors Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07431281 clinical trial report covering Nivolumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071250135 Selexipag Intermittent Claudication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
JPRN-jRCT2071250135 clinical trial report covering Selexipag, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07430956 Cenvacibart Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07430956 clinical trial report covering Cenvacibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07430306 Anifrolumab-FNIA Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07430306 clinical trial report covering Anifrolumab-FNIA, Phase 3, endpoints, sponsor, geography, readout timing and development white space.